Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) have been given a consensus rating of “Hold” by the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $7.33.
NMTC has been the subject of several research reports. Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the company a “buy” rating in a research report on Friday, August 14th.
Read Our Latest Stock Report on NMTC
Insider Activity at NeuroOne Medical Technologies
Institutional Investors Weigh In On NeuroOne Medical Technologies
A number of hedge funds have recently modified their holdings of NMTC. Susquehanna International Group LLP purchased a new position in shares of NeuroOne Medical Technologies in the second quarter worth about $41,000. Bard Associates Inc. acquired a new position in NeuroOne Medical Technologies during the second quarter worth about $929,000. Finally, BlackRock Inc. acquired a new position in NeuroOne Medical Technologies during the second quarter worth about $76,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.
NeuroOne Medical Technologies Stock Down 4.0%
NMTC stock opened at $1.07 on Tuesday. The stock has a market capitalization of $9.79 million, a P/E ratio of -1.13 and a beta of 0.77. The firm has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $2.88. NeuroOne Medical Technologies has a 52 week low of $0.96 and a 52 week high of $6.12.
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. The company had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.17 million. On average, analysts expect that NeuroOne Medical Technologies will post -0.39 earnings per share for the current year.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation is a medical device company focused on developing and commercializing technologies for recording, monitoring, and treating neurological disorders. Its products are designed for use by neurosurgeons and neurologists in procedures involving the brain and nervous system, including the diagnosis and treatment of epilepsy and other neurological conditions.
The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used to record electrical activity in the brain.
Featured Articles
- Five stocks we like better than NeuroOne Medical Technologies
- The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
- Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
